Federico Ng, MD
Internal Medicine · San Antonio, TXNPI 1528061488
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,223 and has fallen 52.1% since, to $586 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$741
- GSK$646
- AstraZeneca$636
- Novo Nordisk$394
- Ironshore Pharmaceuticals Inc.$262
- Lilly USA, LLC$234
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,893100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $741 |
| GSK | 44 | $646 |
| AstraZeneca(2 entities) | 32 | $636 |
| Novo Nordisk | 23 | $394 |
| Ironshore Pharmaceuticals Inc. | 14 | $262 |
| Lilly USA, LLC | 14 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $211 |
| Collegium Pharmaceutical, Inc. | 13 | $184 |
| Acerus Pharmaceuticals Corporation | 13 | $169 |
| Lundbeck LLC | 2 | $150 |
| Bayer | 8 | $144 |
| Genentech USA, Inc. | 6 | $118 |
| Neos Therapeutics, LP | 6 | $110 |
| Abbott | 5 | $106 |
| Antares Pharma, Inc. | 7 | $102 |
| Medtronic | 3 | $68 |
| Shield Therapeutics Inc | 4 | $61 |
| Corium, LLC | 4 | $51 |
| Exact Sciences | 3 | $51 |
| Boston Scientific | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Clarus Therapeutics Inc. | 2 | $34 |
| Adlon Therapeutics L.p. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Organon | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Exeltis, USA Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$125
How this compares
$4,893 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 101 | $120,350 |
| Humira PenAdalimumab | 12 | $81,738 |
| TrulicityDulaglutide | 57 | $71,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $30,058 |
| KerendiaFinerenone | 26 | $29,832 |
| FarxigaDapagliflozin Propanediol | 15 | $20,380 |
| XareltoRivaroxaban | 11 | $14,124 |
| OzempicSemaglutide | 13 | $14,014 |
| JardianceEmpagliflozin | 13 | $11,468 |
| Victoza 3-PakLiraglutide | 12 | $9,580 |
| VascepaIcosapent Ethyl | 24 | $9,151 |
| Liothyronine Sodium | 102 | $5,293 |
| Rosuvastatin Calcium | 169 | $3,739 |
| Testosterone Cypionate | 27 | $3,476 |
| Varenicline Tartrate | 12 | $3,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $234 | $194,284173 claims |
| GSKTrelegy Ellipta | $646 | $30,05827 claims |
| BayerKerendia | $144 | $29,83226 claims |
| AstraZenecaFarxiga | $636 | $20,38015 claims |
| Novo NordiskOzempic | $394 | $14,01413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in San Antonio
- Manuel RodriguezSan Antonio$263K
- Matthew CatesSan Antonio$248K
- Fabian Rodas OchoaSan Antonio$68K
- Darius BuzenasSan Antonio$49K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.